Takeda

Access Takeda's directory of downloadable reports on sustainability, corporate overview, and annual reports.

Entyvio Shows Higher Rates of Mucosal Healing Versus TNFα-Antagonist Therapy in Real-World Data Analysis

OSAKA, Japan, and CAMBRIDGE, Massachusetts, July 9, 2025 – Takeda (TSE:4502/NYSE:TAK) today filed its Corporate Governance Report with the Tokyo Stock Exchange (“TSE”) in accordance with the regulations for TSE listed companies.

Takeda says its employees are united by a shared purpose.

The page describes the composition and purpose of the Takeda Pharmaceuticals Board of Directors, which oversees strategic decisions.

The Takeda leadership team develops strategy and executes it with patients at the center.

Rhonda Pacheco is President of Takeda’s U.S. Business Unit and U.S. Country Head, and a member of Takeda’s Executive Team.

Takeda's vision is to discover and deliver treatments, guided by its commitments to patients, its people, and the planet.

Takeda Pharmaceuticals says it is committed to saving five million children's lives each year and describes its initiatives in child health.

The company’s papers outline its position on material issues that arise in realizing its purpose and vision.

Introducing Takeda Garden for Medicinal Plant Conservation, Kyoto.

The page provides Takeda Pharmaceutical Company Limited's global corporate address and contact information for media inquiries, investor relations, comments, and questions. It also mentions the FAQs and Privacy Notice.

Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.

The page states that using the internet site represents consent to its terms and conditions.

Takeda R&D president Andy Plump plans to retire in June 2027 after more than a decade leading the company’s research organization. The article describes him as the architect of Takeda’s R&D overhaul and says he will remain in the role until the company finds a successor.

Sep 2026 · BioPharma DiveNews article

Takeda receives FDA approval for Mimrylo (rusfertide) to treat polycythemia vera. The first-in-class hepcidin mimetic marks the company’s second new-drug approval under CEO Julie Kim.

Aug 2026 · Fierce PharmaNews article

The FDA approves Takeda Pharmaceuticals America's Mimrylo (rusfertide) for adults with polycythemia vera, a rare blood disorder. The drug is the first treatment of its kind to mimic hepcidin to control red blood cell overproduction in adults with the condition.

Aug 2026 · U.S. Food and Drug AdministrationNews article

Takeda gains FDA approval for Orzeyful (oveporexton), a first-in-class treatment for narcolepsy type 1. The medicine addresses the condition’s root cause by mimicking the orexin cycle; its launch remains pending Drug Enforcement Administration review.

Aug 2026 · Fierce PharmaNews article